Compare · LMDX vs VRAX
LMDX vs VRAX
Side-by-side comparison of LumiraDx Limited (LMDX) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMDX and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 1883.3x VRAX ($1.2M).
- VRAX has hit the wire 3 times in the past 4 weeks while LMDX has been quiet.
- LMDX has more recent analyst coverage (4 ratings vs 1 for VRAX).
- Company
- LumiraDx Limited
- Virax Biolabs Group Limited
- Price
- $0.02-53.80%
- $0.16+0.50%
- Market cap
- $2.23B
- $1.2M
- 1M return
- -
- -13.45%
- 1Y return
- -
- -83.38%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 0
- 3
- Recent ratings
- 4
- 1
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 3 filed by new insider Haight Nelson M
- Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
- SEC Form 3 filed by new insider Mccracken Nigel William
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 3 filed by new insider Foster James Alexander Cunliffe
- SEC Form 3 filed by new insider Norton Evan Michael
- SEC Form 3 filed by new insider Davis Jason